UKPOL.CO.UK

Tag: John Glen

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, what discussions NICE has had with the EU institutions on the proposed Joint Action 3 on health technology appraisals.

    George Freeman

    In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).

    NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.

    The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.

  • John Glen – 2016 Parliamentary Question to the Department for Education

    John Glen – 2016 Parliamentary Question to the Department for Education

    The below Parliamentary question was asked by John Glen on 2016-09-05.

    To ask the Secretary of State for Education, whether her Department holds data on the (a) use and (b) prevalence of setting and streaming in schools in England.

    Nick Gibb

    In-school organisation, such as streaming or setting, is a matter for individual schools, and data is not collected or held by the Department on this matter.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, what representations he has received from NICE on the potential merits of a European relative effectiveness assessment to inform health technology appraisals.

    George Freeman

    In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).

    NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.

    The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-10-11.

    To ask the Secretary of State for Health, what plans (a) NICE and (b) NHS England has to issue a consultation on changes to the highly specialised technologies evaluation programme.

    Nicola Blackwood

    The National Institute for Health and Care Excellence and NHS England launched a joint consultation on 13 October 2016 setting out proposed changes to the arrangements for the evaluation and adoption of new technologies, including on the methodology for the evaluation of highly specialised technologies.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-02-29.

    To ask the Secretary of State for Health, what discussions he has had with NICE on its policy on a European relative effectiveness assessment for new drugs.

    George Freeman

    In October 2015, the Department nominated the National Institute for Health and Care Excellence (NICE) as a partner organisation in the planned third Joint Action on Health Technology Assessment (HTA).

    NICE has advised that it has had a number of discussions with European Commission officials, as well as other partner organisations, about NICE’s participation in this planned Joint Action.

    The Department is responsible for the policy framework for the assessment of health technologies and officials remain in close contact with NICE regarding the European Union collaboration in HTA, including the proposals for the production of joint products as part of the third Joint Action.

  • John Glen – 2016 Parliamentary Question to the Department of Health

    John Glen – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2016-10-11.

    To ask the Secretary of State for Health, whether he plans to appeal NICE’s draft guidance on asfotase alfa for treating paediatric-onset hypophosphatasia, issued in September 2016.

    Nicola Blackwood

    The National Institute for Health and Care Excellence (NICE) is currently evaluating the costs and benefits of asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia to determine whether it can be recommended for national commissioning by NHS England.

    There has not yet been an opportunity for stakeholders to appeal NICE’s recommendations on the use of asfotase alfa for treating paediatric-onset hypophosphatasia. NICE published a second iteration of draft guidance for consultation on 22 September 2016 and the closing date for comments was 13 October 2016. NICE’s independent Evaluation Committee will now consider the comments received in response to the consultation before deciding on the next steps for the evaluation.

  • John Glen – 2015 Parliamentary Question to the Department of Health

    John Glen – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2015-10-20.

    To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, what assessment his Department has made of the date on which he will issue a tender for extended half-life products.

    George Freeman

    The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.

    NHS England has made no decision to develop a clinical commissioning policy for ‘extended half-life products’. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.

  • John Glen – 2015 Parliamentary Question to the Department of Health

    John Glen – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2015-10-20.

    To ask the Secretary of State for Health, pursuant to the Answer of 14 October 2015 to Question 10868, on blood diseases: drugs, when NHS England plans to take a decision on the development of a clinical commissioning policy for extended half-life products; what discussions NHS England has had to date on such a clinical commissioning policy; and if he will make a statement.

    George Freeman

    The timing of the tender is effectively predicated on the availability of licensed products. The Department is in dialogue with those suppliers understood to be concerned in this market to understand their potential capabilities.

    NHS England has made no decision to develop a clinical commissioning policy for ‘extended half-life products’. The potential need for policy will remain under review by the Clinical Reference Group with input from the Department’s Commercial Medicines Unit, as manufacturer’s products achieve licence and procurements are completed.

  • John Glen – 2022 Statement on Tax Credits and Child Benefit – Review of Rates

    John Glen – 2022 Statement on Tax Credits and Child Benefit – Review of Rates

    The statement made by John Glen, the Chief Secretary to the Treasury, in the House of Commons on 17 November 2022.

    The Tax Credits Act 2002 and the Social Security Administration Act 1992 place a statutory duty on His Majesty’s Treasury to review the rates of tax credits and child benefit each year in line with the general level of prices. There is a further statutory duty on the Treasury to increase guardian’s allowance in line with price growth. I have now concluded the review for the tax year 2023-24.

    I have decided to increase tax credits and child benefit rates in line with the consumer price index (CPI) for the year to September 2022. Guardian’s allowance will also increase by the same rate. This means that:

    The majority of elements and thresholds in working tax credit and child tax credit, including all disability elements, will increase by 10.1% from 6 April 2023. This means, for example, that the basic element of working tax credit will increase from £2,070 to £2,280 per year. In line with established practice and the Office for Budget Responsibility’s expectations in their welfare forecast, the maximum rate of the childcare element, the family element, the withdrawal rate and disregards in tax credits will remain unchanged.

    All rates of child benefit, plus guardian’s allowance, will increase by 10.1 % from 10 April 2023. This means, for example, that the child benefit rate for the eldest child will increase from £21.80 to £24 per week.

    The new rates will apply across the United Kingdom. I will deposit the full list of these rates in the Libraries of both Houses shortly.

  • John Glen – 2015 Parliamentary Question to the Department of Health

    John Glen – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by John Glen on 2015-10-09.

    To ask the Secretary of State for Health, if NHS England will develop a clinical commissioning policy on the use of extended half-life blood clotting factor products in people with haemophilia.

    George Freeman

    The Department plans to tender for extended half-life Clotting Factor VIII and Factor IX for use in the National Health Service once the products are granted European Union licences and are commercially available.

    NHS England has made no decision at this time to whether it will develop a clinical commissioning policy for extended half-life productsbut, through the Clinical Reference Group and discussion with the Department’s Commercial Medicines Unit, will continue to review commissioning of these extended half-life products in the future.